These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14503545)

  • 1. Preventing fungal infections in chronic granulomatous disease.
    Franzblau MJ
    N Engl J Med; 2003 Sep; 349(12):1190-1; author reply 1190-1. PubMed ID: 14503545
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials and rare diseases.
    Lagakos SW
    N Engl J Med; 2003 Jun; 348(24):2455-6. PubMed ID: 12802033
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventing fungal infections in chronic granulomatous disease.
    Verweij PE; Warris A; Weemaes CM
    N Engl J Med; 2003 Sep; 349(12):1190-1; author reply 1190-1. PubMed ID: 14503544
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing fungal infections in chronic granulomatous disease.
    Berger VW
    N Engl J Med; 2003 Sep; 349(12):1190-1; author reply 1190-1. PubMed ID: 13679539
    [No Abstract]   [Full Text] [Related]  

  • 5. Itraconazole to prevent fungal infections in chronic granulomatous disease.
    Gallin JI; Alling DW; Malech HL; Wesley R; Koziol D; Marciano B; Eisenstein EM; Turner ML; DeCarlo ES; Starling JM; Holland SM
    N Engl J Med; 2003 Jun; 348(24):2416-22. PubMed ID: 12802027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misleading statements in industry-sponsored meta-analysis of itraconazole.
    Gøtzsche PC; Johansen HK
    J Clin Oncol; 2005 Dec; 23(36):9428-9; author reply 9429-32. PubMed ID: 16361645
    [No Abstract]   [Full Text] [Related]  

  • 7. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
    Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
    J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy.
    Wang CY; Wu BY; Guo KY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Apr; 23(4):389-90. PubMed ID: 12697487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study.
    Sharpe MD; Ghent C; Grant D; Horbay GL; McDougal J; David Colby W
    Transplantation; 2003 Sep; 76(6):977-83. PubMed ID: 14508365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia.
    Menichetti F
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S181-4. PubMed ID: 15546115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
    Prentice AG; Glasmacher A; Djulbegovic B
    Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France.
    Beauté J; Obenga G; Le Mignot L; Mahlaoui N; Bougnoux ME; Mouy R; Gougerot-Pocidalo MA; Barlogis V; Suarez F; Lanternier F; Hermine O; Lecuit M; Blanche S; Fischer A; Lortholary O;
    Pediatr Infect Dis J; 2011 Jan; 30(1):57-62. PubMed ID: 20700078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Invasive fungal infection: challenge and choice].
    Weng XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1441-2. PubMed ID: 16061015
    [No Abstract]   [Full Text] [Related]  

  • 15. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic granulomatous lung infection caused by the dimorphic fungus Emmonsia sp.
    Wellinghausen N; Kern WV; Haase G; Rozdzinski E; Kern P; Marre R; Essig A; Hetzel J; Hetzel M
    Int J Med Microbiol; 2003 Dec; 293(6):441-5. PubMed ID: 14760976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place for itraconazole in treatment.
    Maertens J; Boogaerts M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.